SHENZHEN, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product's review process for marketing approval in the AD indication.Impressive phase III trial data in ADIts Priority Review is expected to accelerate its NDA approvalRuxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product's expansion into multiple therapeutic areas.Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD.Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001).Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated.Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date.Building an integrated AD solution,strengthening Dermavon’s leadership in dermatologyAD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed.Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care.Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon's market competitiveness and brand influence in the field of skin health.More Information About Ruxolitinib Phosphate CreamRuxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3].The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary).Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurarCMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – CanSino Biologics Inc. (688185.SH/06185.HK) announced that the Company has obtained the Notification of Approval of Supplemental Drug Application issued by the National Medical Products Administration of China (the “NMPA”), pursuant to which, the supplemental application to expand the age range of applicable population of the Company’s Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “MCV4”, trade name: Menhycia (R)) from “children aged from 3 months to 3 years old (47 months)” to “children aged from 3 months to 6 years old (83 months)” has been approved by NMPA.This approval marks an important step forward, underscoring the public health impact of Menhycia (R) while also strengthening its long-term commercial prospects. Under China’s current national immunization schedule, the final pre-school dose of meningococcal vaccination is administered at six years of age. For a long time, multivalent conjugate vaccine options for children over age three have been relatively limited in the domestic market. The newly approved expansion of the eligible age range helps address this gap, providing broader and more appropriate vaccination options for this population.At the same time, the broader eligible population is expected to further unlock Menhycia (R)’s commercialization prospects, and lay a more solid foundation for the product’s promotion and strategic rollout in international markets.Notably, CanSinoBIO issued its Results Forecast For The Year 2025 recently. Forecasting total revenue of RMB 1.04–1.08 billion, a year-on-year increase of 22.88% to 27.61% and net profit attributable to the shareholders of RMB 24.5–29.0 million—marking a return to profitability. The company noted that Menhycia (R), China’s first domestically developed quadrivalent meningococcal conjugate vaccine, continues to drive sustained revenue growth under its innovation-led commercialization strategy. This also signifies that the company is now reaping the commercial benefits of its early investments in vaccine innovation.Leveraging its proprietary platform, first-mover advantages, and accelerating global expansion, the age expansion of Menhycia (R) is expected to further strengthen CanSinoBIO’s competitive position while providing new momentum for sustainable growth. As product coverage broadens and international commercialization advances, the company is well-positioned to enter a new phase of long-term growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – February 22, Galaxy Payroll Group Limited (NASDAQ: GLXG) (“Galaxy” or the “Company”), a Nasdaq-listed human resources solutions provider, today announced that it has formally renewed a five-year strategic cooperation agreement with NIKE China Holding HK Limited (Macau Branch) (“Nike Macau Branch”).Five-Year Renewal with Comprehensive HR Service CoveragePursuant to the agreement, the renewed cooperation term will commence on December 1, 2025 and continue through November 30, 2030. During this period, Galaxy will continue to provide Nike Macau Branch with a comprehensive suite of human resources outsourcing services, including local payroll processing, attendance and leave management, social security and tax compliance filings, as well as advisory services relating to labor regulations and employment policies.This integrated service model is designed to enable Nike Macau Branch to focus on its core retail and brand operations while enhancing overall organizational efficiency and compliance management.Strategic Renewal Reflects Client Confidence and Enhances Revenue VisibilityThe renewal marks an important milestone in the long-standing relationship between the parties and reflects the continued trust placed in Galaxy’s professional capabilities, compliance standards, and service delivery quality by a leading international brand.The execution of a multi-year agreement is expected to enhance the Company’s revenue visibility and cash flow stability over the next five years, further aligning with its capital markets strategy of building a high-quality, resilient, and sustainable business model. While the agreement provides for long-term cooperation, actual results may vary and remain subject to market and operational conditions.Local Expertise and Scalable Service Infrastructure as Core Competitive AdvantagesSince its establishment in 2013, Galaxy has focused on the Hong Kong and Macau markets while progressively expanding its cross-regional service capabilities. The Company has developed deep expertise in Hong Kong and Macau labor laws, taxation, and social security regulations, forming a strong local compliance foundation.Through a service framework that combines standardized operational processes with customized solutions, Galaxy delivers consistency and scalability across its client base. Its proprietary payroll and attendance management platform enhances operational efficiency while supporting data security and business continuity, serving as a key differentiator in attracting and retaining multinational enterprise clients.Throughout prior phases of cooperation, Galaxy has supported Nike Macau Branch in navigating complex employment and compliance environments. The Company’s solutions have demonstrated reliability in accuracy, responsiveness, and risk control, providing a solid foundation for this long-term renewal.Looking Ahead: From Service Delivery to Value Co-CreationEntering the new cooperation cycle, Galaxy intends to further optimize payroll workflows and intelligent attendance systems within the existing service framework. Through enhanced data integration and periodic management reporting, the Company aims to support the client’s ongoing efforts toward standardized and digitalized human resource management.The parties have also agreed to retain flexibility to expand the scope of services through supplemental agreements, enabling the partnership to evolve in alignment with the client’s business development.The renewal of this five-year strategic agreement not only represents long-term recognition of Galaxy’s professional value, but also underscores the sustainability of its business model. It is expected to further strengthen the Company’s brand presence in the Hong Kong, Macau, and broader Asia-Pacific human resources outsourcing markets, while serving as a replicable benchmark case for multinational retail, sports, and consumer brands.As global enterprises increasingly prioritize compliance efficiency, cost optimization, and organizational resilience, Galaxy continues to leverage its localized expertise, robust service infrastructure, and high-quality client base to build sustainable long-term growth momentum.The Company’s management commented: “We will continue to place service capability at the core of our growth strategy, deepen strategic cooperation with existing high-quality clients, and proactively expand relationships with multinational and regional enterprises that offer long-term value, with the goal of delivering steady and sustainable returns to our shareholders.”Contact informationJune TuoTel: (852) 5983-9260Phone: (86)1392-3804-279Intelligent Joy Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 24, 2026 - (ACN Newswire via SeaPRwire.com) – Hong Kong Trade Development Council (HKTDC), in collaboration with Hong Kong Science and Technology Parks Corporation (HKSTP), will lead a delegation of 21 Hong Kong tech companies and institutions to showcase at Mobile World Congress (MWC) 2026—the world’s premier connectivity event, and debut at 4 Years From Now (4YFN) 2026—a global stage for start-ups, taking place concurrently 2-5 March in Barcelona, Spain. Building on the momentum from MWC 2025 — the Delegation will be featuring solutions beyond the Connectivity category, covering focus areas across Devices and Systems, Digital Transformation and support from Ecosystem Partners. The Pavilion duet ought to give a more comprehensive picture of Hong Kong’s innovation and technology (I&T) capabilities in engaging global telecom leaders, enterprise decision-makers, industry partners, and investors, bridging cutting-edge research and development (R&D) into real-world applications and propelling Hong Kong’s I&T sector onto the international stage.Iris Wong, Director, Merchandise Trade and Innovation / Director, External Relations, HKTDC, said, “The Hong Kong Tech Pavilion is an ideal platform for Hong Kong tech enterprises to present their latest R&D achievements at major international tech gatherings, support their journey to explore overseas markets, while highlighting Hong Kong’s strengths as an international innovation and technology hub.”Derek Chim, Head of Startup Ecosystem and Development, HKSTP said, “MWC is a global bellwether for communications technology and tech companies at any stage, to connect with the industry and investors, to have a solid ground that validate solutions, catalyse pilot projects, accelerate commercialisation, and scale internationally.”A series of dialogues and exchanges, spanning from networking reception and themed talks to pitching sessions, will take place throughout the events at the Pavilion to facilitate partnerships and investment opportunities for innovative solutions that are market-ready with high potential for market expansion, in particular, Asmote and Cresento under “Connectivity” make stellar examples of the notion:5G & 6G for Communication, Sensing, and AI computing – Shannon & Turing, (Asmote), located at MWC, specialises in mmWave technology for Integrated Sensing and Communication (ISAC) technology—drone communications and control—rising to the occasion as the city advances its low-altitude economy initiatives, while winning favors for its efficiency in managing industrial scenarios such as smart ports and dark factories. The company previously secured the world’s first 26GHz mmWave 5G commercial communications project, demonstrating its leadership in industrial-grade applications.Smart Performance Insights for Sport – Cresento, located at 4YFN, focused on developing an AI-powered shin guard to deliver real-time insights—performance analytics, team leaderboards, and more—with a design that incorporates into gears that athletes already wear and creates minimal friction for, in particular, football players to adapt, will be moving from prototypes to pilot collaborations with European football clubs, academies and sport tech platforms and distributors.HKTDC continues to join hands with HKSTP to support Hong Kong tech enterprises to “go global” by jointly organising the Hong Kong Tech Pavilion to build bridges linking tech companies with the world. This expedites the industry’s progress in internationalisation to meet the growing demand for I&T globally. This will attract talents, facilitate forward-looking investments and explore opportunities globally, realising the mission of entrepreneurs to reach out to the world and further consolidate Hong Kong’s position as an international I&T hub.Mobile World Congress Barcelona (MWC) & 4 Years From Now (4YFN)Date: 2-5 March 2026Venue: Fira Gran Via, Av. Joan Carles I, 64, 08908 L'Hospitalet de Llobregat, Barcelona, SpainHong Kong Tech Pavilion:MWC – Booth 6E44 at Hall 64YFN – Booth 8.1B31 at Hall 8.1Please visit https://bit.ly/MWC2026HKTech for more information on Hong Kong Tech Pavilion and the exhibitors.Appendix: Full list of 21 tech entities showcasing at Hong Kong Tech Pavilion during MWC and 4YFN 2026 (in alphabetical order)No.Name of Tech Company / InstitutionCategoryMWC 2026 – Booth 6E44 at Hall 61Entoptica LimitedDevices & Systems2eSIXConnectivity3Faraconix Technologies Co., Ltd.Connectivity4FreightAmigo Services LimitedDigital Transformation5Glassdio Scientific Company LimitedConnectivity6Harvest Elite International LimitedDigital Transformation7HongKong Umedia LimitedDevices & Systems8iASPEC Services LimitedDigital Transformation9InvestHKEcosystem Partners10Robocore Technology LimitedDevices & Systems11Shannon & Turing Technology LimitedConnectivity12The Hong Kong Polytechnic UniversityEcosystem Partners13Xeroptix TechnologyDevices & Systems4YFN 2026 – Booth 8.1B31 at Hall 8.114AIGM LimitedDigital Transformation15BWSea Technology (HK) Co., LimitedDigital Transformation16Cresento LimitedDevices & Systems17GoGoChart Technology LimitedDigital Transformation18HairCoSys LimitedDevices & Systems19KNQ Technology LimitedDigital Transformation20Solos Technology LimitedDevices & Systems21Vista Innotech LimitedDevices & SystemsAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.About Hong Kong Science and Technology Parks CorporationHong Kong Science and Technology Parks Corporation (HKSTP) was established in 2001 to create a thriving I&T ecosystem grooming 12 unicorns, more than 16,000 research professionals and around 2,600 technology companies from 24 countries and regions focused on developing healthtech, AI and robotics, fintech and smart city technologies, etc.Our growing innovation ecosystem offers comprehensive support to attract and nurture talent, accelerate and commercialise innovation for technology ventures, with the I&T journey built around our key locations of Hong Kong Science Park in Pak Shek Kok, InnoCentre in Kowloon Tong and three modern InnoParks in Tai Po, Tseung Kwan O and Yuen Long realising a vision of new industrialisation for Hong Kong, where sectors including advanced manufacturing, micro-electronics and biotechnology are being reimagined.Hong Kong Science Park Shenzhen Branch in Futian, Shenzhen plays positive roles in connecting the world and the mainland with our proximity, strengthening cross-border exchange to bring advantages in attracting global talent and allowing possibilities for the development of technology companies in seven key areas: Medtech, big data and AI, robotics, new materials, microelectronics, fintech and sustainability, with both dry and wet laboratories, co-working space, conference and exhibition facilities, and more.Through our R&D infrastructure, startup support and enterprise services, commercialisation and investment expertise, partnership networks and talent traction, HKSTP continues to contribute in establishing I&T as a pillar of growth for Hong Kong.More information about HKSTP is available at www.hkstp.org.Media Contact: Hong Kong Science and Technology Parks CorporationHong Kong Trade Development CouncilAngela LauTel: +852 6535 7611Email: angela.lau@hkstp.orgWinnie KanTel: +852 2584 4055Email: winnie.wy.kan@hktdc.org Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Australia--(ACN Newswire via SeaPRwire.com - February 23, 2026) - Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to announce that the Company has entered into an advertising services agreement (the "Agreement") dated February 19, 2026 with AJO Capital Inc. ("AJO"), whereby AJO will provide marketing and investor awareness services to raise public awareness of GMG, including without limitation, original news articles, podcast and interview content creation, newspaper, television, radio and industry network distribution, as well as social media support (the "Services"). GMG has agreed to a monthly payment of US$26,500 for the provision by AJO of the Services. The Agreement commenced on February 19, 2026 and has an initial term of four (4) months unless earlier terminated. The Agreement may be renewed upon mutual written agreement at least thirty (30) days prior to the expiration of the initial term, subject to any modifications to compensation and payment terms as the parties may agree.AJO is a private company based in New York, United States dedicated to providing financial information and media and communication services. The Company will not issue any securities of the Company to AJO as compensation. To the Company's knowledge, AJO and its directors and officers are arm's length from the Company and do not have any interest, direct or indirect, in the Company or its securities nor do they have any right to acquire such an interest.About GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed to improve the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information, please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward-looking statements", are not historical facts, are made as of the date of this news release and include without limitation, services to be provided by AJO, term and termination of the Agreement and compensation payable to AJO pursuant to the Agreement.Such forward-looking statements are based on a number of assumptions of management, including, without limitation, assumptions regarding the services to be provided by AJO, covenants by AJO under the Agreement, length of the term of the Agreement, termination of the Agreement and compensation payable to AJO pursuant to the Agreement, that the Company will not issue any future securities to AJO as compensation under the Agreement, that AJO acts at arm's length to the Company and none of AJO, its directors nor officers have any direct or indirect interest in the Company and its securities nor do they have any right to acquire such interests. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation, failure by AJO to render services in accordance with the Agreement, breach of the Agreement by either parties, early termination of the Agreement and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285033 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com